Se-Methylselenocysteine (hydrochloride) (Synonyms: Methylselenocysteine, Se-MeSeCys, Se-methyl-L-Selenocysteine) |
Katalog-Nr.GC48914
One-Click Copy Product Info
|
Se-Methylselenocysteine (hydrochloride)(MSC), ein Derivat der Selenocystein-Methylierung, ist eine natürliche, monomethylierte Selenoaminosäure.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 863394-07-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Se-Methylselenocysteine (hydrochloride)(MSC), ein Derivat der Selenocystein-Methylierung, ist eine natürliche, monomethylierte Selenoaminosäure. Se-methylselenocysteine wird hauptsächlich zur Anti-Aging-Behandlung, Selen-Supplementierung, Therapie von Herz-Kreislauf-Erkrankungen und als Antioxidans verwendet[1]. Se-Methylselenocysteine ist oral bioverfügbar und induziert Apoptose[2,3].
Se-methylselenocysteine(100-400 µM; 3 Tage) induziert Apoptose durch Caspase-Aktivierung und Calpain-vermittelte Bax-Spaltung in SKOV-3-Ovarialkarzinomzellen[4]. Se-methylselenocysteine (200 µM; 24 Stunden) kann die durch EA(Elaidinsäure) verursachte Reduktion der Zellviabilität effektiv umkehren[5]. Se-methylselenocysteine konnte in einer optimalen Konzentration von 1 µM die durch Clusterin(Clu)-Knockdown verursachten Veränderungen der antioxidativen Kapazität, des Bcl2/Bax-Verhältnisses und der Caspase-8-Aktivität umkehren und so die Apoptose hemmen und die Zellviabilität erhalten[6].
Se-Methylselenocysteine (0.2 mg/Maus; p.o.; täglich über 14 Tage) verstärkte die Antitumorwirkung von Cisplatin(cis-diamminedichloroplatinum (CDDP)) und Cyclophosphamid in Nacktmäusen mit humanen FaDu- und A253-Kopf-Hals-Xenotransplantaten[7]. Die Behandlung mit Se-methylselenocysteine (0.3 /1/3 mg/kg; 10 Wochen; p.o.) linderte die Leberschädigung. Mit steigender Se-methylselenocysteine-Konzentration nahm der Grad der Lebergewebeschädigung bei den Mäusen allmählich ab[8].
References:
[1]. Johnson WD, Morrissey RL, et,al. Subchronic toxicity studies of Se-methylselenocysteine, an organoselenium compound for breast cancer prevention: Food Chem Toxicol, 2008; 46; 1068-78
[2]. El-Bayoumy K, Sinha R, Mechanisms of mammary cancer chemoprevention by organoselenium compounds: Mutat Res, 2004; 551; 181-97
[3]. Medina D, Thompson H, et,al.Se-methylselenocysteine: A new compound for chemoprevention of breast cancer: Nutr Cancer, 2001; 40; 12-17
[4]. Yeo JK, Cha SD, et,al. Se-methylselenocysteine induces apoptosis through caspase activation and Bax cleavage mediated by calpain in SKOV-3 ovarian cancer cells. Cancer Lett. 2002 Aug 8;182(1):83-92. doi: 10.1016/s0304-3835(02)00075-7. PMID: 12175527.
[5]. Xia J, Xia X, et,al. Protective Effect of Se-Methylselenocysteine on Elaidic Acid-Induced Inflammation in Human Arterial Endothelial Cells. J Nutr Sci Vitaminol (Tokyo). 2020;66(6):577-582. doi: 10.3177/jnsv.66.577. PMID: 33390400.
[6]. Wang C, Zeng Z, et,al. Se-methylselenocysteine inhibits apoptosis induced by clusterin knockdown in neuroblastoma N2a and SH-SY5Y cell lines. Int J Mol Sci. 2014 Nov 18;15(11):21331-47. doi: 10.3390/ijms151121331. PMID: 25411798; PMCID: PMC4264228.
[7]. Cao S, Durrani FA, et,al. Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models. Br J Cancer. 2014 Apr 2;110(7):1733-43. doi: 10.1038/bjc.2014.85. Epub 2014 Mar 11. PMID: 24619073; PMCID: PMC3974093.
[8]. Ding J, Qi C, et,al. Se-Methylselenocysteine Alleviates Liver Injury in Diethylnitrosamine (DEN)-Induced Hepatocellular Carcinoma Rat Model by Reducing Liver Enzymes, Inhibiting Angiogenesis, and Suppressing Nitric Oxide (NO)/Nitric Oxide Synthase (NOS) Signaling Pathway. Med Sci Monit. 2021 Aug 4;27:e929255. doi: 10.12659/MSM.929255. PMID: 34344856; PMCID: PMC8351367.
| Zellexperiment [1]: | |
Zelllinien | SKOV-33-Zellen |
Vorbereitungsmethode | |
Reaktionsbedingungen | 100-400 µM; 3 Tage |
Anwendungen | Se-Methylselenocysteine(MSC) induziert Apoptose in SKOV-33-Zellen. |
| Tierversuch [2]: | |
Tiermodelle | Sprague-Dawley-Ratten(120 bis 150 g) |
Vorbereitungsmethode | Die Ratten wurden zufällig in eine normale Kontrollgruppe(n=16), eine Modellgruppe(n=16) und 3 mit Se-Methylselenocysteine (MSC) behandelte Gruppen(n=48). Die Ratten der normalen Kontrollgruppe erhielten Standardfutter(ohne MSC). Die Ratten der Modellgruppe erhielten über 6 aufeinanderfolgende Wochen fünfmal wöchentlich Standardfutter mit 0.1 mg/kg MSC. |
Dosierungsform | 0.3 /1/3 mg/kg; 10 Wochen; p.o. |
Anwendungen | Die MSC-Behandlung linderte die Leberschädigung. Mit steigender MSC-Konzentration verringerte sich der Grad der Lebergewebe-Schädigung allmählich. |
References: | |
| Cas No. | 863394-07-4 | SDF | |
| Überlieferungen | Methylselenocysteine, Se-MeSeCys, Se-methyl-L-Selenocysteine | ||
| Canonical SMILES | C[Se]C[C@H](N)C(O)=O.Cl | ||
| Formula | C4H9NO2Se •HCl | M.Wt | 218.6 |
| Löslichkeit | DMF: 1 mg/ml,DMSO: 1 mg/ml,PBS (pH 7.2): 10 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.5746 mL | 22.8728 mL | 45.7457 mL |
| 5 mM | 914.9 μL | 4.5746 mL | 9.1491 mL |
| 10 mM | 457.5 μL | 2.2873 mL | 4.5746 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)